Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Prostatic Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × SB939 compound × Clear all
NCT00504296 2023-08-04

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Canadian Cancer Trials Group

Phase 1 Completed
39 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01075308 2023-08-04

SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Completed
32 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡